Poly (ADP-Ribose) Polymerase Inhibitors: Talazoparib in Ovarian Cancer and Beyond
Stergios Boussios(Medway NHS Foundation Trust), Nicholas Pavlidis(University of Ioannina)
Cited by 138
Related Papers
Multiple-Treatments Meta-analysis of Chemotherapy and Targeted Therapies in Advanced Breast Cancer
|JNCI Journal of the National Cancer Institute|2008|524
Survival Benefits With Diverse Chemotherapy Regimens for Ovarian Cancer: Meta-analysis of Multiple Treatments
|JNCI Journal of the National Cancer Institute|2006|182
Survival and disease-progression benefits with treatment regimens for advanced colorectal cancer: a meta-analysis
|The Lancet Oncology|2007|160
ESMO / ASCO Recommendations for a Global Curriculum in Medical Oncology Edition 2016
|ESMO Open|2016|129
Comparative survival with diverse chemotherapy regimens for cancer of unknown primary site: Multiple-treatments meta-analysis
|Cancer Treatment Reviews|2009|128